The estimated Net Worth of Joshua B Muntner is at least $464 dollars as of 25 July 2017. Joshua Muntner owns over 2,000 units of ContraFect Corp stock worth over $464 and over the last 9 years Joshua sold CFRX stock worth over $0.
Joshua has made over 1 trades of the ContraFect Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently Joshua bought 2,000 units of CFRX stock worth $2,480 on 25 July 2017.
The largest trade Joshua's ever made was buying 2,000 units of ContraFect Corp stock on 25 July 2017 worth over $2,480. On average, Joshua trades about 333 units every 0 days since 2015. As of 25 July 2017 Joshua still owns at least 2,000 units of ContraFect Corp stock.
You can see the complete history of Joshua Muntner stock trades at the bottom of the page.
Joshua's mailing address filed with the SEC is 30 FIFTH AVENUE, APT 12 F, NEW YORK, NY, 10011.
Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz, eIndustrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
ContraFect Corp executives and other stock owners filed with the SEC include: